JP2022545191A - 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物 - Google Patents

活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物 Download PDF

Info

Publication number
JP2022545191A
JP2022545191A JP2022509096A JP2022509096A JP2022545191A JP 2022545191 A JP2022545191 A JP 2022545191A JP 2022509096 A JP2022509096 A JP 2022509096A JP 2022509096 A JP2022509096 A JP 2022509096A JP 2022545191 A JP2022545191 A JP 2022545191A
Authority
JP
Japan
Prior art keywords
vaccinia virus
cancer
inhibitor
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022509096A
Other languages
English (en)
Japanese (ja)
Inventor
テ‐ホ ファン，
モン チョ，
ジェ‐ジュン キム，
Original Assignee
バイオノックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオノックス インコーポレイテッド filed Critical バイオノックス インコーポレイテッド
Publication of JP2022545191A publication Critical patent/JP2022545191A/ja
Priority to JP2024221508A priority Critical patent/JP2025038139A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022509096A 2019-08-29 2020-08-31 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物 Pending JP2022545191A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024221508A JP2025038139A (ja) 2019-08-29 2024-12-18 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190106736 2019-08-29
KR10-2019-0106736 2019-08-29
PCT/KR2020/011648 WO2021040496A1 (ko) 2019-08-29 2020-08-31 백시니아 바이러스 및 과립백혈구 형성 억제제를 유효성분으로 포함하는 암 치료용 약학 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024221508A Division JP2025038139A (ja) 2019-08-29 2024-12-18 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物

Publications (1)

Publication Number Publication Date
JP2022545191A true JP2022545191A (ja) 2022-10-26

Family

ID=74685712

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022509096A Pending JP2022545191A (ja) 2019-08-29 2020-08-31 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物
JP2024221508A Pending JP2025038139A (ja) 2019-08-29 2024-12-18 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024221508A Pending JP2025038139A (ja) 2019-08-29 2024-12-18 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物

Country Status (8)

Country Link
US (1) US20220288143A1 (https=)
EP (1) EP4023235A4 (https=)
JP (2) JP2022545191A (https=)
KR (1) KR102661908B1 (https=)
CN (1) CN114630683A (https=)
AU (1) AU2020337054B9 (https=)
CA (1) CA3152973A1 (https=)
WO (1) WO2021040496A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7704419B2 (ja) * 2019-06-27 2025-07-08 バイオノックス インコーポレイテッド 安全性及び抗がん効果が改善された腫瘍溶解性ウイルス
KR102739298B1 (ko) * 2021-04-02 2024-12-06 주식회사 바이오녹스 바이러스 벡터 유래 항암요법 표적 단백질 및 이에 특이적으로 결합하는 결합 분자 또는 이의 단편
CN118443941A (zh) * 2024-04-29 2024-08-06 山东大学齐鲁医院 中性粒细胞作为诊疗膀胱癌的靶标的应用
CN119955859A (zh) * 2025-01-24 2025-05-09 郑州大学 F14l基因缺失和表达腺苷脱氨酶的溶瘤痘苗病毒载体的构建方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508156A (ja) * 2012-01-25 2015-03-16 ディーエヌエートリックス インコーポレイテッド バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法
WO2018057755A1 (en) * 2016-09-21 2018-03-29 Thorne Stephen H High mobility group box i mutant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
EP2073823A1 (en) * 2006-10-13 2009-07-01 Medigene AG Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
CA2709292A1 (en) * 2009-07-10 2011-01-10 The Governors Of The University Of Alberta Oncolytic viruses and methods for treating neoplastic disorders
KR101632897B1 (ko) * 2013-04-10 2016-06-23 신라젠(주) 백시니아 바이러스로부터 유래한 신규한 항암 바이러스 ｈｂｂ３０１
WO2017205674A1 (en) * 2016-05-25 2017-11-30 Arizona Board Of Regents On Behalf Of Arizona State University Oncolytic vaccinia virus mutants and using same for cancer treatment
US11857585B2 (en) * 2017-12-28 2024-01-02 Bionoxx Inc. Oncolytic virus improved in safety and anticancer effect
CN112584852A (zh) * 2018-06-19 2021-03-30 百欧恩泰美国公司 新抗原及其用途
CA3150829A1 (en) * 2019-08-26 2021-03-04 Bionoxx Inc. Pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredient for treatment of cancer
CN114364390A (zh) * 2019-08-26 2022-04-15 拜耳诺克斯有限公司 用于治疗癌症的包含抗癌病毒、免疫检查点抑制剂和羟基脲作为活性成分的药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508156A (ja) * 2012-01-25 2015-03-16 ディーエヌエートリックス インコーポレイテッド バイオマーカーならびに腫瘍溶解性ウイルスと免疫調節法とを用いる併用療法
WO2018057755A1 (en) * 2016-09-21 2018-03-29 Thorne Stephen H High mobility group box i mutant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. Vol.124, Issue 12, 4778, JPN6023019152, 2014, pages 1 - 3, ISSN: 0005511107 *
CANCERS, vol. Vol.11, Issue 5, JPN6023019151, 16 May 2019 (2019-05-16), pages 1 - 22, ISSN: 0005511106 *
NATURE COMMUNICATIONS, vol. Vol.9, Article number: 4342, JPN6023019150, 2018, pages 1 - 15, ISSN: 0005511105 *

Also Published As

Publication number Publication date
EP4023235A1 (en) 2022-07-06
JP2025038139A (ja) 2025-03-18
CN114630683A (zh) 2022-06-14
US20220288143A1 (en) 2022-09-15
AU2020337054B2 (en) 2024-10-17
WO2021040496A1 (ko) 2021-03-04
AU2020337054A1 (en) 2022-03-10
KR102661908B1 (ko) 2024-04-29
CA3152973A1 (en) 2021-03-04
EP4023235A4 (en) 2023-03-29
AU2020337054B9 (en) 2024-11-07
KR20210027209A (ko) 2021-03-10

Similar Documents

Publication Publication Date Title
JP2025038139A (ja) 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物
Wang et al. Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
CN112004545B (zh) 免疫-溶瘤的经修饰的痘苗天坛病毒和治疗癌症的方法
CA3004738A1 (en) Modified immune cells and uses thereof
Corti et al. Novel immune targets for the treatment of triple-negative breast cancer
JP2024038026A (ja) 活性成分として抗がんウイルス、免疫チェックポイント阻害剤及びヒドロキシ尿素を含む、がんを処置するための医薬組成物
Drougkas et al. CAR-T cell therapy in pancreatic and biliary tract cancers: an updated review of clinical trials
JP7326663B2 (ja) がんの処置のための活性成分としてワクシニアウイルス及びヒドロキシ尿素を含む医薬組成物
Shi et al. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo
Qin et al. Antitumor effect of neoantigen-reactive T cells combined with PD1 inhibitor therapy in mouse lung cancer
Zhao et al. Immunotherapy for high-grade endometrial stromal sarcoma: a narrative review bridging molecular insights to clinical translation
TW202511490A (zh) 裝甲ｔ細胞
Nagy et al. Heterodimeric IL-15 (hetIL-15) reduces circulating tumor
Yeung et al. Immunotherapy in Pancreatic Cancer
CN121362259A (zh) 新型PDL1-CAR-γδT细胞的构建及其抗肿瘤应用
WO2025093824A1 (en) Oncolytic adenovirus, immune checkpoint inhibitor and chemoterapeutic agent combination therapy of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241219